Cytokinetics, Inc. : Cytokinetics Announces 1-for-6 Reverse Stock Split

   Cytokinetics, Inc. : Cytokinetics Announces 1-for-6 Reverse Stock Split

South   San   Francisco,    CAJune24,   2013-Cytokinetics,    Incorporated 
(NASDAQ:CYTK) announcedtoday that it has filed a Certificate of Amendment  to 
its Amended and Restated Certificate of Incorporation to effect a  one-for-six 
reverse stock split  of its common  stock, effective as  of 5:00 p.m.  Eastern 
time today. A series of alternate amendments to effect a reverse stock  split 
were  approved  by  the  Company's  stockholders  at  its  Annual  Meeting  of 
Stockholders held on  May 22,  2013, and  the specific  one-for-six ratio  was 
subsequently approved by the Company's Board of Directors.

At the effective  time of the  reverse stock  split, every six  shares of  the 
Company's issued and outstanding common stock will be automatically  converted 
into one issued and outstanding share  of common stock, without any change  in 
par value per share.  The reverse stock  split will affect  all shares of  the 
Company's common stock outstanding immediately prior to the effective time  of 
the reverse stock  split, as  well as  the number  of shares  of common  stock 
available for  issuance  under  the  Company's  equity  incentive  plans.  In 
addition, the reverse  stock split will  effect a reduction  in the number  of 
shares of common  stock issuable upon  the conversion of  shares of  preferred 
stock  or  upon  the  exercise  of  stock  options  or  warrants   outstanding 
immediately prior  to  the  effectiveness  of  the  reverse  stock  split.  No 
fractional shares  will be  issued as  a result  of the  reverse stock  split. 
Stockholders who would  otherwise be  entitled to receive  a fractional  share 
will receive, in lieu thereof, a cash payment based on the closing sales price
of the Company's common stock as reported on the NASDAQ Capital Market on  the 
last business  day immediately  preceding the  effective date  of the  reverse 
stock split. The  Company's common  stock will  begin trading  on the  NASDAQ 
Capital Market on  a split-adjusted basis  when the market  opens on  Tuesday, 
June 25, 2013. The new CUSIP number for the Company's common stock  following 
the reverse stock split is 23282W 605.

The reverse  stock split  will reduce  the number  of shares  of common  stock 
issued and outstanding from approximately 163.6 million to approximately  27.3 
million. Concurrently, the authorized number  of shares of common stock  will 
be reduced to 81.5 million.

Computershare Trust Company,  N.A. is  acting as exchange  agent and  transfer 
agent for the reverse stock split. Computershare will provide instructions to
stockholders regarding  the  process  for  exchanging  their  pre-split  stock 
certificates  for  post-split  stock  certificates.  Additional   information 
regarding the reverse  stock split can  be found in  the Company's  definitive 
proxy statement filed with the Securities and Exchange Commission on April  2, 
2013.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide to develop and commercialize omecamtiv mecarbil and  related 
compounds,   subject    to    Cytokinetics'    specified    development    and 
commercialization  participation   rights.   Cytokinetics   is   independently 
developing tirasemtiv and CK-2127107, both fast skeletal muscle activators, as
potential treatments  for  diseases  and medical  conditions  associated  with 
aging, muscle wasting  or neuromuscular dysfunction.  Tirasemtiv is  currently 
the subject of a Phase II clinical trials program and has been granted  orphan 
drug  designation  and  fast   track  status  by  the   U.S.  Food  and   Drug 
Administration and  orphan  medicinal  product  designation  by  the  European 
Medicines Agency for the potential treatment of amyotrophic lateral sclerosis,
a debilitating disease  of neuromuscular  impairment in  which treatment  with 
tirasemtiv produced potentially clinically relevant pharmacodynamic effects in
Phase II trials. All of these  drug candidates have arisen from  Cytokinetics' 
muscle biology  focused  research  activities and  are  directed  towards  the 
cytoskeleton. The  cytoskeleton is  a complex  biological infrastructure  that 
plays a fundamental role within every human cell. Additional information about
Cytokinetics can be obtained at www.cytokinetics.com.

Contact:
Cytokinetics, Inc.
Joanna L. Goldstein (Investors & Media)
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1711723
 
Press spacebar to pause and continue. Press esc to stop.